Incretin-based therapy for treating patients with type 2 diabetes

2011 ◽  
Vol 152 (48) ◽  
pp. 1931-1940 ◽  
Author(s):  
György Jermendy
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Practice ◽  
New Drugs ◽  
Clinical Experiences ◽  
Dipeptidyl Peptidase 4 ◽  
New Class ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Near Future

In the last couple of years, a new class of antidiabetic drugs became available for the clinical practice. Due to the intensive research, several new drugs reached the market. Among the incretinmimetics both the GLP-1 (glucagon like peptide-1)-receptor agonist exenatide and the GLP-1-analogue liraglutide can be used for treatment. As for incretin enhancers (dipeptidyl-peptidase-4 [DPP-4]-inhibitors), sitagliptin, vildagliptin and saxagliptin are available in Hungary, linagliptin will be introduced to the market in the near future. In clinical practice, any incretin-based new drugs can be used for treating patients with type 2 diabetes, preferably in combination with metformin. The clinical experiences with these new drugs are reviewed focusing on both the benefits and the potential side-effects of the particular compounds. Orv. Hetil., 2011, 152, 1931–1940.

scholarly journals Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications

2016 ◽  
Vol 13 (3) ◽  
pp. 32-36
Author(s):  
Tat'yana Morgunova ◽  
Valentin Fadeev
Keyword(s):  
Type 2 Diabetes ◽  
Meta Analysis ◽  
Original Research ◽  
Dipeptidyl Peptidase 4 ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
The Stability

This article is dedicated to the problem of glycaemic durability of drugs used in treatment of type 2 diabetes. The results of studies comparing durability of glycemic control as monotherapy or in combination of metformin with different drugs: dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, sulfonylurea, inhibitors of sodium-glucose cotransporter-2 are shown. The article discusses the results of original research and meta-analysis.

Therapeutic Targets Underlying the Evolution of Potential Anti-Diabetic Agents: A Comprehensive Review

2021 ◽  
Vol 18 ◽  
Author(s):  
Siddhita Tiwari ◽  
Paranjeet Kaur ◽  
Deepali Gupta ◽  
Saumik Chaudhury ◽  
Manish Chaudhary ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Beta Cell ◽  
Glucose Level ◽  
Glycogen Phosphorylase ◽  
Dipeptidyl Peptidase ◽  
The Body ◽  
Dipeptidyl Peptidase 4 ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

: Type 2 Diabetes is termed as a chronic metabolic syndrome that occurs due to hyperglycaemia. Type 2 diabetes is growing worldwide really fast. Looking at all the circumstances, it was recognized that insulin check and Beta-cell brokenness are essential issues that are responsible for the unforeseen development of diabetes. Drugs for diabetes were found to have glucose level lessening impacts in the body and they were named as Glucagon-like peptide 1, amylin. Amylin is one of the hormones that show its action after having a meal; they have correlated activity to the pancreatic hormones. GLP-1 speedily corrupts via dipeptidyl-peptidase-4 in-vivo that leads to a decline in the said feasibility. Some other efficacious biological medicines that are being used for Type-2 Diabetes are 11beta-HSD-1 inhibitors or rivals in relation to glucocorticoids receptor, some other for reducing hepatic glucose level these are rival of glucagon receptor or maybe inhibitors to glycogen phosphorylase or fructose-1,6-biphosphatase, last but not least mounting urinary discarding of superfluity glucose those are SGLT inhibitors. Moreover, treatments related to Incretin can be glucagon-like peptide-1 [GLP-1] inhibitors and dipeptidyl peptidase 4 [DPP-4] inhibitors. Certain Non-incretin beta-cell stimulants are also in the phase of developments and they are glucokinase activators, G-protein-coupled receptors. These are soothing, antagonistic towards the oxidizing agent. Targets that cause glucose stimulant effect were glucose-6-phosphatase, glycogen phosphorylase and inhibition of same causes vice-versa. Some more novel targets are yet to be found; these superiors will additionally target metabolic ailment, as talking about the present situation it is one novel and primary clinical ailment that individual in the world estimated to suffer from the threat of 2nd type of diabetes.

Pharmacotherapy for Type 2 Diabetes Mellitus: What’s Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

2021 ◽  
pp. 089719002110490
Author(s):  
Mary J. Elder ◽  
Emily J. Ashjian
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Glucagon Secretion ◽  
New Drugs ◽  
Beneficial Effects ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Glucagon-like peptide-1 (GLP-1), an incretin hormone, is known to lower glucose levels, suppress glucagon secretion, and slow gastric emptying. These properties make GLP-1 an ideal target in treating type 2 diabetes mellitus (T2DM). There are many FDA-approved GLP-1 agonists on the market today, several of which have demonstrated benefit beyond improving glycemic control. Given the beneficial effects of GLP-1 agonists in patients with T2DM, new drugs are in development that combine the mechanism of action of GLP-1 receptor agonism with novel mechanisms and with drugs that promote GLP-1 secretion. These agents are designed to improve glycemic control and target greater body weight reduction. This article discusses new GLP-1 drugs in the pipeline for the treatment of T2DM.

Sign in / Sign up

Export Citation Format

Share Document